Clinical Trials Browser

Neoplasm Metastasis × Capecitabine × Breast × Clear all

NCT07007559 2026-04-13

ASPEN-09-03

Phase 2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT04895358 2026-03-11

KEYNOTE-B49

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT05104866 2026-02-04

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Phase 3 Active not recruiting

732 enrolled 22 charts 3 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT05374512 2026-01-27

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06247995 2025-11-06

NeoB-Cap1

Phase 1/2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3 Active not recruiting

557 enrolled 22 charts 2 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT04158362 2025-09-22

AMBRE

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02734290 2025-03-10

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Phase 1/2 Active not recruiting

29 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02954055 2024-02-26

METEORA-II

Phase 2 Completed

140 enrolled 11 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02754011 2023-12-07

GEP14-LEECAP

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT01300962 2023-12-04

Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00807859 2022-11-08

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT04355858 2022-07-26

MULAN

Phase 2 Unknown

Breast Neoplasms, Neoplasm Metastasis

NCT05438706 2022-06-30

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Phase 2 Unknown

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02595320 2021-12-20

X7-7

Phase 2 Unknown

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03326674 2021-07-30

CONTESSA

Phase 3 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT03858972 2021-07-30

CONTESSA 2

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT01783444 2021-02-26

BOLERO-6

Phase 2 Completed

309 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02650752 2021-01-26

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT01471847 2020-12-09

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00080301 2020-11-02

Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Phase 3 Completed

752 enrolled 22 charts

Breast Neoplasms, Neoplasm Metastasis

NCT04274933 2020-10-29

A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Phase 1 Terminated

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01387373 2020-10-05

Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT01917279 2020-07-23

CAMELLIA

Phase 3 Unknown

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Skin Diseases

NCT00741260 2018-09-05

Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

Phase 1/2 Completed

105 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00777101 2018-08-09

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Phase 2 Completed

233 enrolled 16 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02248571 2017-11-13

IMPROVE

Phase 4 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00684216 2017-09-14

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

Phase 2/3 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT02474186 2017-08-03

Phase II Study for Solid Metastatic Tumors

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01640665 2016-09-16

Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors

Phase 1 Completed

BreastGastrointestinal

Breast Neoplasms, Digestive System Neoplasms, Neoplasm Metastasis

NCT00338247 2016-04-06

EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Approved for marketing

Breast Neoplasms, Neoplasm Metastasis

NCT01069796 2016-03-17

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT00468585 2016-01-22

Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model

Phase 1/2 Completed

62 enrolled 9 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01067989 2015-07-08

Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT00795678 2013-08-02

Chemotherapeutic Agents in Brain/Breast

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis

NCT00534417 2013-02-01

Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Completed

41 enrolled 13 charts

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00967031 2013-01-18

Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases

Phase 2 Completed

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT00227656 2012-12-11

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

Phase 2 Terminated

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT00037609 2012-10-24

Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients

Phase 1/2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00657137 2012-03-15

APRiCOT-B

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT00629148 2011-07-07

Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT01126138 2011-05-04

Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

Phase 3 Unknown

Breast Neoplasms, Neoplasm Metastasis, Carcinoma, Ductal, Breast

NCT00270491 2011-02-25

Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00078572 2010-12-13

Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer

Phase 3 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT01196455 2010-09-08

Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms, Neoplasm Metastasis

NCT01195298 2010-09-06

Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms, Neoplasm Metastasis

NCT00081796 2008-08-21

Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer

Phase 3 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00324610 2006-05-18

Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen

Phase 1/2 Unknown

Breast Neoplasms, Neoplasm Metastasis